Abstract
Patients with severe aplastic anemia (SAA) can be successfully treated with bone marrow transplantation (BMT) or immunosuppressive therapy (IS). The current outcome using both forms of therapy among 3,669 patients treated in Europe between 1976 and 1998 is reviewed. Significant progress has been made and the overall risk of failure is now low, with survival rates greater than 80% for both treatments. Chronic graft-versus-host disease (GvHD) remains a problem for BMT patients, and carries a high risk of lethal complications. On the other hand, IS patients are exposed to late failure due to relapse or clonal/malignant diseases. First-line BMT from identical siblings is compared with IS therapy in an intent-to-treat analysis of 1,765 patients, regardless of subsequent transplant status. The outcome of SAA patients has improved considerably over time and is influenced by patient variables such as severity of the disease and age, but also by the choice of the Initial treatment. Copyright (C) 2000 by W.B. Saunders Company.
| Original language | English |
|---|---|
| Pages (from-to) | 69-80 |
| Number of pages | 12 |
| Journal | Seminars in Hematology |
| Volume | 37 |
| Issue number | 1 |
| Publication status | Published - Jan 2000 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Treatment of acquired severe aplastic anemia : Bone marrow transplantation compared with immunosuppressive therapy - The European Group for blood and marrow transplantation experience. / Bacigalupo, Andrea; Brand, Ronald; Oneto, Rosi; Bruno, Barbara; Socié, Gerard; Passweg, Jakob; Locasciulli, Anna; Van Lint, Maria Teresa; Tichelli, André; McCann, Shaun; Marsh, Judith; Ljungman, Per; Hows, Jill; Marin, Pedro; Schrezenmeier, Hubert.
In: Seminars in Hematology, Vol. 37, No. 1, 01.2000, p. 69-80.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of acquired severe aplastic anemia
T2 - Bone marrow transplantation compared with immunosuppressive therapy - The European Group for blood and marrow transplantation experience
AU - Bacigalupo, Andrea
AU - Brand, Ronald
AU - Oneto, Rosi
AU - Bruno, Barbara
AU - Socié, Gerard
AU - Passweg, Jakob
AU - Locasciulli, Anna
AU - Van Lint, Maria Teresa
AU - Tichelli, André
AU - McCann, Shaun
AU - Marsh, Judith
AU - Ljungman, Per
AU - Hows, Jill
AU - Marin, Pedro
AU - Schrezenmeier, Hubert
PY - 2000/1
Y1 - 2000/1
N2 - Patients with severe aplastic anemia (SAA) can be successfully treated with bone marrow transplantation (BMT) or immunosuppressive therapy (IS). The current outcome using both forms of therapy among 3,669 patients treated in Europe between 1976 and 1998 is reviewed. Significant progress has been made and the overall risk of failure is now low, with survival rates greater than 80% for both treatments. Chronic graft-versus-host disease (GvHD) remains a problem for BMT patients, and carries a high risk of lethal complications. On the other hand, IS patients are exposed to late failure due to relapse or clonal/malignant diseases. First-line BMT from identical siblings is compared with IS therapy in an intent-to-treat analysis of 1,765 patients, regardless of subsequent transplant status. The outcome of SAA patients has improved considerably over time and is influenced by patient variables such as severity of the disease and age, but also by the choice of the Initial treatment. Copyright (C) 2000 by W.B. Saunders Company.
AB - Patients with severe aplastic anemia (SAA) can be successfully treated with bone marrow transplantation (BMT) or immunosuppressive therapy (IS). The current outcome using both forms of therapy among 3,669 patients treated in Europe between 1976 and 1998 is reviewed. Significant progress has been made and the overall risk of failure is now low, with survival rates greater than 80% for both treatments. Chronic graft-versus-host disease (GvHD) remains a problem for BMT patients, and carries a high risk of lethal complications. On the other hand, IS patients are exposed to late failure due to relapse or clonal/malignant diseases. First-line BMT from identical siblings is compared with IS therapy in an intent-to-treat analysis of 1,765 patients, regardless of subsequent transplant status. The outcome of SAA patients has improved considerably over time and is influenced by patient variables such as severity of the disease and age, but also by the choice of the Initial treatment. Copyright (C) 2000 by W.B. Saunders Company.
UR - http://www.scopus.com/inward/record.url?scp=12944332070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12944332070&partnerID=8YFLogxK
M3 - Article
C2 - 10676912
AN - SCOPUS:12944332070
VL - 37
SP - 69
EP - 80
JO - Seminars in Hematology
JF - Seminars in Hematology
SN - 0037-1963
IS - 1
ER -